The Doudna Lab
Exploring molecular mechanisms of RNA-mediated gene regulation
The Doudna lab pursues mechanistic understanding of fundamental biological processes involving RNA molecules. Research in the lab is currently focused on three major areas: bacterial immunity via the CRISPR system, RNA interference, and translational control logic. We utilize diverse techniques including X-ray crystallography, high-throughput sequencing, biochemistry, molecular biology, and eukaryotic cell culture. Explore our research further by selecting a focus area below.
Conflicts of Interest
- Non-financial: J. Doudna is executive director of the Innovative Genomics Initiative at UC Berkeley and UCSF.
- Financial: J. Doudna is a co-founder of Editas Medicine, Intellia Therapeutics and Caribou Biosciences and a scientific advisor to Caribou, Intellia, eFFECTOR Therapeutics and Driver.
- Science funding: HHMI, NIH, NSF, Roche, Pfizer, Paul Allen Institute, Keck Foundation
- Institutional: J. Doudna is employed by HHMI and works at the University at California Berkeley. UC Berkeley and HHMI have patents pending for CRISPR technologies on which she is an inventor.